Study finds that most neurologists plan to prescribe oral MS drugs when approved this year
Posted Sep 08 2010 5:08am
NEW YORK–(BUSINESS WIRE)–In a study published this week by Majestic Research, almost 60% of neurologists expressed unaided concern about the side effects/safety of oral MS therapies in development, including NVS’s Gilenia and MRK/EMD Serono’s oral cladribine. Despite their concerns, the vast majority of neurologists expect to prescribe these drugs if they are approved, as the new oral MS therapies are expected to be highly efficacious and more convenient for patients than available injectable therapies.
Caroline says: A recent study showed that 84% of neurologists polled plan to prescribe Novartis' Gilenia (FTY-720) and Serono's cladribine for some of their RRMS patients when they are approved later this year (end of September for Gilenia, later in 2010 for cladribine). However, until safety concerns for both drugs are resolved, they will most likely be prescribed as second-line and third-line agents, despite the fact that their FDA approval will probably be as first-line agents.